Kyttaro’s patent portfolio was developed by the scientific team at Apceth Biopharma GmbH (established in 2007 and operations sold to Hitachi Chemical in 2019).

In 2019, Apceth Biopharma GmbH licensed its patent portfolio to JuntuCell GmbH.

In 2021, Kyttaro Therapeutics was incorporated in the United States to commercialize this unique patent portfolio. Juntucell GmbH granted Kyttaro Therapeutics the worldwide, exclusive license to 61 patents together with all know-how, for applications of MSC-AAT, MSC-Cytokine and MSC-Klotho.

Kyttaro Therapeutics is poised to commence clinical trials in Europe and the US for COVID-19 and GvHD applications, with others to follow. We are seeking clinical partners in the US both to produce MSC-AAT and to engage in clinical trials with us.